FDA: Ignore the false racial equity argument for keeping Makena

A pharma company is arguing that Makena should be kept on the market because it may work in Black people. But it doesn't work in any people.

Related Keywords

Martha Nolan ,Covis Pharma ,Human Development ,Drug Administration ,Bristol Myers Squibb ,Us National Institute Of Child Health ,Luxembourg Based Covis Pharma ,Apollo Global ,Child Health ,Adeza Biomedical ,New England Journal ,Optimizing Neonatal Gestation ,